Table 3 Logistic regression analysis of the risk factors of postoperative AE-ILD.

From: Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients

Variables

ALL (n = 152)

Lobectomy (n = 77)

Sublobar resection (n = 75)

OR

95% CI

P-value

OR

95% CI

P-value

OR

95% CI

P-value

(a) Univariate analysis

Age, years

0.975

0.911–1.045

0.475

0.949

0.865–1.041

0.266

1.025

0.920–1.143

0.652

Sex, male

Not calculated

Not calculated

Not calculated

Smoking history, pack-years

1.010

0.999–1.020

0.076

1.013

0.999–1.026

0.058

1.003

0.984–1.022

0.771

VC, % predicted

0.965

0.936–0.994

0.020*

0.948

0.895–1.005

0.072

0.963

0.924–1.004

0.075

FVC, % predicted

0.970

0.938–1.003

0.077

0.969

0.916–1.025

0.267

0.965

0.922–1.011

0.132

FEV1, % predicted

0.970

0.943–1.000

0.045*

0.959

0.915–1.005

0.083

0.976

0.937–1.017

0.247

FEV1/FVC, %

1.036

0.986–1.089

0.163

1.046

0.974–1.123

0.221

1.032

0.959–1.109

0.399

DLco, % predicted

0.979

0.950–1.010

0.180

0.947

0.902–0.995

0.030*

1.004

0.961–1.049

0.859

Histology, NSCLC

0.536

0.106–2.715

0.451

0.188

0.027–1.297

0.090

Not calculated

Stage I vs. II-III

0.775

0.233–2.573

0.677

0.594

0.151–2.342

0.457

Not calculated

Primary tumor size, mm

1.024

0.990–1.059

0.167

1.036

0.991–1.083

0.119

0.996

0.932–1.063

0.896

ILD pattern, UIP

2.111

0.760–5.863

0.157

3.786

0.960–14.933

0.057

1.212

0.251–5.851

0.811

Preoperative steroid use, + 

1.251

0.257–6.089

0.781

1.130

0.122–10.50

0.915

1.452

0.152–13.87

0.746

Preoperative pirfenidone use, + 

1.625

0.178–14.80

0.667

Not calculated

Not calculated

Surgical procedure, lobectomy

1.45

0.521–4.033

0.477

–

–

–

–

–

–

Operative time, min

1.010

1.003–1.018

0.008*

1.017

1.005–1.030

0.007*

1.005

0.995–1.015

0.321

Bleeding volume, mL

1.002

1.001–1.004

0.002*

1.003

1.000–1.005

0.019*

1.004

0.999–1.009

0.131

HMGB1, ng/mL

1.141

1.050–1.239

0.002*

1.170

1.054–1.298

0.003*

0.926

0.653–1.313

0.665

(b) Multivariate analysis including operative time

VC, % predicted

0.966

0.923–1.011

0.132

0.983

0.906–1.068

0.697

0.946

0.891–1.004

0.070

FEV1, % predicted

0.994

0.953–1.038

0.795

0.977

0.908–1.052

0.541

1.001

0.947–1.059

0.959

Operative time, min

1.010

1.002–1.018

0.010*

1.017

1.003–1.032

0.018*

1.008

0.998–1.019

0.119

HMGB1, ng/mL

1.119

1.023–1.224

0.014*

1.178

1.037–1.338

0.012*

0.792

0.534–1.175

0.247

(c) Multivariate analysis including bleeding volume

VC, % predicted

0.961

0.913–1.011

0.125

0.979

0.896–1.070

0.640

0.932

0.867–1.002

0.055

FEV1, % predicted

0.997

0.950–1.047

0.910

0.955

0.880–1.036

0.269

1.025

0.956–1.099

0.488

Bleeding volume, mL

1.003

1.001–1.005

0.009*

1.003

1.001–1.005

0.017*

1.006

1.000–1.013

0.045*

HMGB1, ng/mL

1.114

1.023–1.215

0.014*

1.170

1.027–1.332

0.019*

0.785

0.524–1.175

0.240

  1. AE-ILD acute exacerbation of interstitial lung disease; OR Odds ratio; CI confidence interval; DLco diffusing capacity for carbon monoxide; FEV1 forced expiratory volume in one second; FVC forced vital capacity; HMGB1 high-mobility group box 1; ILD interstitial lung disease; NSCLC non-small cell lung cancer; SCLC small cell lung cancer; UIP usual interstitial pneumonia; VC vital capacity.
  2. *P < 0.05 Logistic regression analysis.
Back to article page